{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:05:30Z","timestamp":1790521530181,"version":"4.1.0"},"reference-count":242,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["GACR 17-16169S"],"award-info":[{"award-number":["GACR 17-16169S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bbadis.2021.166206","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T05:03:19Z","timestamp":1624942999000},"page":"166206","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity"],"prefix":"10.1016","volume":"1867","author":[{"given":"Lukas","family":"Cerveny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Murthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frantisek","family":"Staud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2021.166206_bb0005","unstructured":"World Health Organization, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids, [accessed 22nd October 2020]."},{"key":"10.1016\/j.bbadis.2021.166206_bb0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.285.6.709","article-title":"Understanding the timing of HIV transmission from mother to infant","volume":"285","author":"Kourtis","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.bbadis.2021.166206_bb0015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0140-6736(98)01419-6","article-title":"International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Ghent International Working Group on Mother-to-Child Transmission of HIV","volume":"352","author":"Leroy","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166206_bb0020","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/OLQ.0000000000000528","article-title":"Cuba validated as the first country to eliminate mother-to-child transmission of human immunodeficiency virus and congenital syphilis: lessons learned from the implementation of the Global validation methodology","volume":"43","author":"Caffe","year":"2016","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0025","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/INF.0000000000002290","article-title":"Epidemiology of perinatal HIV transmission in the United States in the era of its elimination","volume":"38","author":"Nesheim","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.bbadis.2021.166206_bb0030","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/0033354918789912","article-title":"Perinatal HIV service coordination: closing gaps in the HIV care continuum for pregnant women and eliminating perinatal HIV transmission in the United States","volume":"133","author":"Andrews","year":"2018","journal-title":"Public Health Rep."},{"key":"10.1016\/j.bbadis.2021.166206_bb0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/21505594.2019.1697136","article-title":"Mini review: prevention of mother-child transmission of HIV: 25\u00a0years of continuous progress toward the eradication of pediatric AIDS?","volume":"11","author":"Blanche","year":"2020","journal-title":"Virulence"},{"key":"10.1016\/j.bbadis.2021.166206_bb0040","unstructured":"Panel on Treatment of Pregnant Women with HIV Infection and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in transmission in the United States. Available at http:\/\/aidsinfo.nih.gov\/contentfiles\/lvguidelines\/PerinatalGL.pdf. Accessed (12th October 2020)."},{"key":"10.1016\/j.bbadis.2021.166206_bb0045","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s40262-020-00915-w","article-title":"Innovative approaches for pharmacology studies in pregnant and lactating women: a viewpoint and lessons from HIV","volume":"59","author":"Eke","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1172\/JCI12094","article-title":"Mother-to-infant transmission of HIV-1: the placenta fights back","volume":"107","author":"Spector","year":"2001","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2021.166206_bb0055","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2217\/fvl.11.119","article-title":"Host factors that influence mother-to-child transmission of HIV-1: genetics, coinfections, behavior and nutrition","volume":"6","author":"Ellington","year":"2011","journal-title":"Futur. Virol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0060","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/ije\/dyr055","article-title":"In utero and intra-partum HIV-1 transmission and acute HIV-1 infection during pregnancy: using the BED capture enzyme-immunoassay as a surrogate marker for acute infection","volume":"40","author":"Marinda","year":"2011","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0065","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1097\/QAD.0b013e3283489d45","article-title":"Association of recent HIV infection and in-utero HIV-1 transmission","volume":"25","author":"Taha","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0070","first-page":"797","article-title":"Human immunodeficiency virus infection in pregnancy","volume":"101","author":"Minkoff","year":"2003","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/jp.2008.187","article-title":"Role of placenta in the vertical transmission of human immunodeficiency virus","volume":"29","author":"Al-Husaini","year":"2009","journal-title":"J. Perinatol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0080","doi-asserted-by":"crossref","unstructured":"S. Lagaye, M. Derrien, E. Menu, C. Coito, E. Tresoldi, P. Mauclere, G. Scarlatti, G. Chaouat, F. Barre-Sinoussi, M. Bomsel, H.I.V. European Network for the Study of In Utero Transmission of, Cell-to-cell contact results in a selective translocation of maternal human immunodeficiency virus type 1 quasispecies across a trophoblastic barrier by both transcytosis and infection, J Virol, 75 (2001) 4780\u20134791.","DOI":"10.1128\/JVI.75.10.4780-4791.2001"},{"key":"10.1016\/j.bbadis.2021.166206_bb0085","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0165-2478(94)00191-S","article-title":"Anti-HIV effect of beta subunit of human chorionic gonadotropin (beta hCG) in vitro","volume":"44","author":"Bourinbaiar","year":"1995","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.bbadis.2021.166206_bb0090","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1742-4690-9-101","article-title":"Placental Hofbauer cells limit HIV-1 replication and potentially offset mother to child transmission (MTCT) by induction of immunoregulatory cytokines","volume":"9","author":"Johnson","year":"2012","journal-title":"Retrovirology"},{"key":"10.1016\/j.bbadis.2021.166206_bb0095","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1128\/JVI.75.5.2194-2203.2001","article-title":"Perinatal transmission of major, minor, and multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum","volume":"75","author":"Dickover","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0100","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0140-6736(90)90349-A","article-title":"HIV-1 in trophoblastic and villous Hofbauer cells, and haematological precursors in eight-week fetuses","volume":"335","author":"Lewis","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166206_bb0105","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJM199606203342501","article-title":"Obstetrical factors and the transmission of human immunodeficiency virus type 1 from mother to child. The women and infants transmission study","volume":"334","author":"Landesman","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0110","doi-asserted-by":"crossref","unstructured":"G. John-Stewart, D. Mbori-Ngacha, R. Ekpini, E.N. Janoff, J. Nkengasong, J.S. Read, P. Van de Perre, M.L. Newell, I.A.S.W.G.o.H.I.V.i.W.C. Ghent, Breast-feeding and transmission of HIV-1, J Acquir Immune Defic Syndr, 35 (2004) 196\u2013202.","DOI":"10.1097\/00126334-200402010-00015"},{"key":"10.1016\/j.bbadis.2021.166206_bb0115","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1128\/JVI.06578-11","article-title":"Differential transmission of HIV traversing fetal oral\/intestinal epithelia and adult oral epithelia","volume":"86","author":"Tugizov","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0120","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1086\/314854","article-title":"Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1","volume":"180","author":"Semba","year":"1999","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/089033449901500407","article-title":"Mastitis and immunological factors in breast milk of human immunodeficiency virus-infected women","volume":"15","author":"Semba","year":"1999","journal-title":"J. Hum. Lact."},{"key":"10.1016\/j.bbadis.2021.166206_bb0130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.antiviral.2009.09.016","article-title":"HIV reservoirs, latency, and reactivation: prospects for eradication","volume":"85","author":"Dahl","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.bbadis.2021.166206_bb0135","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1086\/515576","article-title":"HIV-1 infection of trophoblasts is independent of gp120\/CD4 interactions but relies on heparan sulfate proteoglycans","volume":"195","author":"Vidricaire","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0140","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0042-6822(02)00040-5","article-title":"Transmission of HIV-1 infection between trophoblast placental cells and T-cells take place via an LFA-1-mediated cell to cell contact","volume":"307","author":"Arias","year":"2003","journal-title":"Virology"},{"key":"10.1016\/j.bbadis.2021.166206_bb0145","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2249.1992.tb03031.x","article-title":"Human trophoblast cells express CD4 and are permissive for productive infection with HIV-1","volume":"88","author":"David","year":"1992","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0150","doi-asserted-by":"crossref","first-page":"15832","DOI":"10.1074\/jbc.M210470200","article-title":"The low viral production in trophoblastic cells is due to a high endocytic internalization of the human immunodeficiency virus type 1 and can be overcome by the pro-inflammatory cytokines tumor necrosis factor-alpha and interleukin-1","volume":"278","author":"Vidricaire","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbadis.2021.166206_bb0155","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1016\/j.celrep.2020.03.016","article-title":"Endogenous retroviral envelope syncytin induces HIV-1 spreading and establishes HIV reservoirs in placenta","volume":"30","author":"Tang","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbadis.2021.166206_bb0160","doi-asserted-by":"crossref","first-page":"12304","DOI":"10.1128\/JVI.79.19.12304-12310.2005","article-title":"Impact of the placental cytokine-chemokine balance on regulation of cell-cell contact-induced human immunodeficiency virus type 1 translocation across a trophoblastic barrier in vitro","volume":"79","author":"Derrien","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0165","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3851\/IMP1918","article-title":"Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid)","volume":"16","author":"Else","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb0170","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0143-4004(88)90007-0","article-title":"Morphological aspects of the placenta in HIV pregnancies","volume":"9","author":"Jauniaux","year":"1988","journal-title":"Placenta"},{"key":"10.1016\/j.bbadis.2021.166206_bb0175","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1086\/317634","article-title":"Placental abnormalities associated with human immunodeficiency virus type 1 infection and perinatal transmission in Bangkok, Thailand","volume":"182","author":"Schwartz","year":"2000","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0180","first-page":"85","article-title":"Pregnancy outcome and placental weights: their relationship to HIV-1 infection","volume":"70","author":"Gichangi","year":"1993","journal-title":"East Afr. Med. J."},{"key":"10.1016\/j.bbadis.2021.166206_bb0185","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/163.5.1134","article-title":"Pathology and human immunodeficiency virus expression in placentas of seropositive women","volume":"163","author":"Chandwani","year":"1991","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0190","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJM198906223202501","article-title":"Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire","volume":"320","author":"Ryder","year":"1989","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0195","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1055\/s-2007-994545","article-title":"Vertical human immunodeficiency virus transmission: a study of placental pathology in relation to maternal risk factors","volume":"11","author":"Backe","year":"1994","journal-title":"Am. J. Perinatol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0200","doi-asserted-by":"crossref","first-page":"639","DOI":"10.5858\/arpa.2017-0421-RS","article-title":"Placental cytomegalovirus infection","volume":"143","author":"Lindholm","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0205","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijgo.2012.06.016","article-title":"Morphologic changes in the placentas of HIV-positive women and their association with degree of immune suppression","volume":"119","author":"Vermaak","year":"2012","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.bbadis.2021.166206_bb0210","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/modpathol.3800418","article-title":"Chorioamnionitis is associated with placental transmission of human immunodeficiency virus-1 subtype E in the early gestational period","volume":"18","author":"Bhoopat","year":"2005","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0215","first-page":"269","article-title":"Placental villous lesions in HIV-1 infection treated with zidovudine","volume":"79","author":"Castejon","year":"2011","journal-title":"Ginecol. Obstet. Mex."},{"key":"10.1016\/j.bbadis.2021.166206_bb0220","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/S2352-3018(15)00207-6","article-title":"Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis","volume":"3","author":"Wedi","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.bbadis.2021.166206_bb0225","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12251","article-title":"HIV-exposed uninfected children: a growing population with a vulnerable immune system?","volume":"176","author":"Afran","year":"2014","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0230","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00281-016-0578-9","article-title":"Impact of HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health","volume":"38","author":"Altfeld","year":"2016","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0235","doi-asserted-by":"crossref","first-page":"6989717","DOI":"10.1155\/2018\/6989717","article-title":"Immune dysfunction and coinfection with human immunodeficiency virus and schistosoma japonicum in Yi people","volume":"2018","author":"Yang","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.bbadis.2021.166206_bb0240","doi-asserted-by":"crossref","unstructured":"J.E. Lawn, M. Kinney, Preterm birth: now the leading cause of child death worldwide, Sci Transl Med, 6 (2014) 263ed221.","DOI":"10.1126\/scitranslmed.aaa2563"},{"key":"10.1016\/j.bbadis.2021.166206_bb0245","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12977-017-0331-z","article-title":"Breast milk and in utero transmission of HIV-1 select for envelope variants with unique molecular signatures","volume":"14","author":"Nakamura","year":"2017","journal-title":"Retrovirology"},{"key":"10.1016\/j.bbadis.2021.166206_bb0250","doi-asserted-by":"crossref","first-page":"13820","DOI":"10.1038\/s41598-017-13218-1","article-title":"Role of HIV exposure and infection in relation to neonatal GBS disease and rectovaginal GBS carriage: a systematic review and meta-analysis","volume":"7","author":"Cools","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2021.166206_bb0255","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S2352-4642(17)30024-X","article-title":"Effects of poverty on interacting biological systems underlying child development","volume":"1","author":"Jensen","year":"2017","journal-title":"Lancet Child Adolesc. Health"},{"key":"10.1016\/j.bbadis.2021.166206_bb0260","unstructured":"Joint United Nations Programme on HIV\/AIDS, Miles to go, closing gaps, breaking barriers, rightning injustice, global AIDS update 2018; https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/miles-to-go_en.pdf [accesssed 18th December 2020]."},{"key":"10.1016\/j.bbadis.2021.166206_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1586\/14787210.2015.999667","article-title":"Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis","volume":"13","author":"Hurst","year":"2015","journal-title":"Expert Rev. Anti-Infect. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb0270","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/cid\/civ578","article-title":"No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception","volume":"61","author":"Mandelbrot","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0275","unstructured":"Joint United Nations Programme on HIV\/AIDS, https:\/\/www.unaids.org\/en\/keywords\/children [accessed 18th December 2020]."},{"key":"10.1016\/j.bbadis.2021.166206_bb0280","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/s12913-020-05381-5","article-title":"Integrating the prevention of mother-to-child transmission of HIV into primary healthcare services after AIDS denialism in South Africa: perspectives of experts and health care workers - a qualitative study","volume":"20","author":"Mutabazi","year":"2020","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.bbadis.2021.166206_bb0285","doi-asserted-by":"crossref","first-page":"200","DOI":"10.2471\/BLT.18.217471","article-title":"Implementing prevention policies for mother-to-child transmission of HIV in rural Malawi, South Africa and United Republic of Tanzania, 2013\u20132016","volume":"97","author":"Jones","year":"2019","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.bbadis.2021.166206_bb0290","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1056\/NEJM199411033311801","article-title":"Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group","volume":"331","author":"Connor","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0295","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2174\/138920009788897993","article-title":"Variation of drug kinetics in pregnancy","volume":"10","author":"Pavek","year":"2009","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.bbadis.2021.166206_bb0300","doi-asserted-by":"crossref","unstructured":"F.T. Aweeka, A. Stek, B.M. Best, C. Hu, D. Holland, A. Hermes, S.K. Burchett, J. Read, M. Mirochnick, E.V. Capparelli, A.C.T.G.P.P.T. International Maternal Pediatric Adolescent, Lopinavir protein binding in HIV-1-infected pregnant women, HIV Med, 11 (2010) 232-238.","DOI":"10.1111\/j.1468-1293.2009.00767.x"},{"key":"10.1016\/j.bbadis.2021.166206_bb0305","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1093\/jac\/dkx176","article-title":"Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?","volume":"72","author":"Metsu","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0310","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/QAI.0b013e31827fd47e","article-title":"Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines","volume":"63","author":"Patterson","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0315","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40262-018-0684-z","article-title":"Pharmacokinetics of HIV-integrase inhibitors during pregnancy: mechanisms, clinical implications and knowledge gaps","volume":"58","author":"van der Galien","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb0320","doi-asserted-by":"crossref","unstructured":"T.R. Cressey, L. Harrison, J. Achalapong, P. Kanjanavikai, O. Patamasingh Na Ayudhaya, P. Liampongsabuddhi, T. Siriwachirachai, C. Putiyanun, P. Suriyachai, C. Tierney, N. Salvadori, D. Chinwong, L. Decker, Y. Tawon, T.V. Murphy, N. Ngo-Giang-Huong, G.K. Siberry, G. Jourdain, T.A.P.S.T. i, Tenofovir exposure during pregnancy and postpartum in women receiving tenofovir disoproxil fumarate for the prevention of mother-to-child transmission of hepatitis B virus, Antimicrob Agents Chemother, 62 (2018).","DOI":"10.1128\/AAC.01686-18"},{"key":"10.1016\/j.bbadis.2021.166206_bb0325","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002160","article-title":"Pregnancy-associated changes in pharmacokinetics: a systematic review","volume":"13","author":"Pariente","year":"2016","journal-title":"PLoS Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0330","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3389\/fphar.2016.00239","article-title":"Etravirine pharmacokinetics in HIV-infected pregnant women","volume":"7","author":"Mulligan","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0335","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/17425255.2020.1754792","article-title":"Pharmacokinetics of HIV therapies in pregnant patients: an update","volume":"16","author":"Neary","year":"2020","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0340","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/dmd.112.050245","article-title":"Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?","volume":"41","author":"Isoherranen","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb0345","doi-asserted-by":"crossref","unstructured":"T.S. Tracy, R. Venkataramanan, D.D. Glover, S.N. Caritis, H. National Institute for Child, U. Human Development Network of Maternal-Fetal-Medicine, Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy, Am J Obstet Gynecol, 192 (2005) 633\u2013639.","DOI":"10.1016\/j.ajog.2004.08.030"},{"key":"10.1016\/j.bbadis.2021.166206_bb0350","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1053\/beog.2001.0231","article-title":"Drugs in pregnancy. Pharmacokinetics in pregnancy","volume":"15","author":"Dawes","year":"2001","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0355","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0163-7258(80)90085-6","article-title":"Drug disposition and pharmacokinetics in the maternal-placental-fetal unit","volume":"10","author":"Krauer","year":"1980","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb0360","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1111\/j.1471-0528.1984.tb03700.x","article-title":"Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: an analysis of fetal-maternal pairs","volume":"91","author":"Krauer","year":"1984","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0365","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2165\/00003088-198207040-00004","article-title":"Plasma protein binding of drugs in pregnancy","volume":"7","author":"Perucca","year":"1982","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb0370","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAI.0000000000002261","article-title":"Darunavir pharmacokinetics with an increased dose during pregnancy","volume":"83","author":"Eke","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0375","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/jac\/dky567","article-title":"Evaluating darunavir\/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling","volume":"74","author":"Schalkwijk","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0380","doi-asserted-by":"crossref","unstructured":"A. Colbers, D. Hawkins, C. Hidalgo-Tenorio, M. van der Ende, A. Gingelmaier, K. Weizsacker, K. Kabeya, G. Taylor, J. Rockstroh, J. Lambert, J. Molto, C. Wyen, S.T. Sadiq, J. Ivanovic, C. Giaquinto, D. Burger, P. network, Atazanavir exposure is effective during pregnancy regardless of tenofovir use, Antivir Ther, 20 (2015) 57-64.","DOI":"10.3851\/IMP2820"},{"key":"10.1016\/j.bbadis.2021.166206_bb0385","doi-asserted-by":"crossref","unstructured":"M. Mirochnick, B.M. Best, A.M. Stek, E.V. Capparelli, C. Hu, S.K. Burchett, S.S. Rossi, E. Hawkins, M. Basar, E. Smith, J.S. Read, I.s.S. Team, Atazanavir pharmacokinetics with and without tenofovir during pregnancy, J Acquir Immune Defic Syndr, 56 (2011) 412\u2013419.","DOI":"10.1097\/QAI.0b013e31820fd093"},{"key":"10.1016\/j.bbadis.2021.166206_bb0390","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/QAI.0000000000000668","article-title":"Pharmacokinetics of once versus twice daily darunavir in pregnant HIV-infected women","volume":"70","author":"Stek","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0395","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1128\/AAC.01197-15","article-title":"No need for lopinavir dose adjustment during pregnancy: a population pharmacokinetic and exposure-response analysis in pregnant and nonpregnant HIV-infected subjects","volume":"60","author":"Salem","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0400","doi-asserted-by":"crossref","unstructured":"M. Mirochnick, B.M. Best, A.M. Stek, E. Capparelli, C. Hu, S.K. Burchett, D.T. Holland, E. Smith, S. Gaddipati, J.S. Read, P.s.S. Team, Lopinavir exposure with an increased dose during pregnancy, J Acquir Immune Defic Syndr, 49 (2008) 485-491.","DOI":"10.1097\/QAI.0b013e318186edd0"},{"key":"10.1016\/j.bbadis.2021.166206_bb0405","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/QAI.0b013e318289b4d2","article-title":"Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy","volume":"63","author":"Kreitchmann","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0410","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1081\/DMR-100104402","article-title":"Human alpha-1-glycoprotein and its interactions with drugs","volume":"33","author":"Israili","year":"2001","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bbadis.2021.166206_bb0415","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1124\/dmd.112.044677","article-title":"Boosting of HIV protease inhibitors by ritonavir in the intestine: the relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice","volume":"40","author":"Holmstock","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb0420","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1124\/dmd.111.041400","article-title":"CYP3A4-mediated lopinavir bioactivation and its inhibition by ritonavir","volume":"40","author":"Li","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb0425","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.reprotox.2018.05.008","article-title":"Interactions of protease inhibitors atazanavir and ritonavir with ABCB1, ABCG2, and ABCC2 transporters: effect on transplacental disposition in rats","volume":"79","author":"Cerveny","year":"2018","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0430","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1128\/AAC.01089-12","article-title":"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro","volume":"56","author":"Lepist","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0435","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1097\/QAD.0000000000002163","article-title":"Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint","volume":"33","author":"Boyd","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0440","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1097\/QAD.0000000000001992","article-title":"Elvitegravir\/cobicistat pharmacokinetics in pregnant and postpartum women with HIV","volume":"32","author":"Momper","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0445","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/ciy161","article-title":"Pharmacokinetics, pharmacodynamics, and pharmacogenetics of efavirenz 400\u00a0mg once daily during pregnancy and post-partum","volume":"67","author":"Lamorde","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0450","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1473-3099(15)70060-5","article-title":"Efficacy and safety of efavirenz 400\u00a0mg daily versus 600\u00a0mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study","volume":"15","author":"E.S. Group","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0455","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1468-1293.2011.00965.x","article-title":"Effect of pregnancy on emtricitabine pharmacokinetics","volume":"13","author":"Stek","year":"2012","journal-title":"HIV Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0460","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/01.aids.0000210609.52836.d1","article-title":"Impact of pregnancy on abacavir pharmacokinetics","volume":"20","author":"Best","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0465","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/314431","article-title":"Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring","volume":"178","author":"Moodley","year":"1998","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0470","unstructured":"V. Bukkems, C. Necsoi, C.H. Tenorio, C. Garcia, J. Rockstroh, C. Schwarze-Zander, J.S. Lambert, D. Burger, D. Konopnicki, A. Colbers, P. network, Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study, Clin Infect Dis, (2020)."},{"key":"10.1016\/j.bbadis.2021.166206_bb0475","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jpba.2017.07.003","article-title":"Current antiviral drugs and their analysis in biological materials - part II: antivirals against hepatitis and HIV viruses","volume":"147","author":"Novakova","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbadis.2021.166206_bb0480","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jpba.2017.06.071","article-title":"Current antiviral drugs and their analysis in biological materials-part I: antivirals against respiratory and herpes viruses","volume":"147","author":"Novakova","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.bbadis.2021.166206_bb0485","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/FTD.0000000000000735","article-title":"Therapeutic drug monitoring of HIV antiretroviral drugs in pregnancy: a narrative review","volume":"42","author":"O\u2019Kelly","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.bbadis.2021.166206_bb0490","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/bcp.12685","article-title":"Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women","volume":"80","author":"De Sousa Mendes","year":"2015","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0495","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40262-015-0325-8","article-title":"Physiologically based modelling of darunavir\/ritonavir pharmacokinetics during pregnancy","volume":"55","author":"Colbers","year":"2016","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb0500","unstructured":"M. Gockenbach, Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy (oral abstract 16). 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs. Noordwijk, the Netherlands. 14\u201316 May 2019. Available at: http:\/\/regist2.virology-education.com\/presentations\/2019\/20AntiviralPK\/33_Gockenbach.pdf. [accessed 19th November 2020]."},{"key":"10.1016\/j.bbadis.2021.166206_bb0505","unstructured":"U.S. Food and Drug Administration. HIV Treatment Information for Pregnant Patients. https:\/\/www.fda.gov\/drugs\/hiv-treatment\/hiv-treatment-information-pregnant-patients [accessed 2nd December 2020]."},{"key":"10.1016\/j.bbadis.2021.166206_bb0510","doi-asserted-by":"crossref","first-page":"736","DOI":"10.3109\/1061186X.2012.716847","article-title":"Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal drug exposure","volume":"20","author":"Staud","year":"2012","journal-title":"J. Drug Target."},{"key":"10.1016\/j.bbadis.2021.166206_bb0515","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1095\/biolreprod.112.105064","article-title":"Organic cation transporter 3 (OCT3\/SLC22A3) and multidrug and toxin extrusion 1 (MATE1\/SLC47A1) transporter in the placenta and fetal tissues: expression profile and fetus protective role at different stages of gestation","volume":"88","author":"Ahmadimoghaddam","year":"2013","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.bbadis.2021.166206_bb0520","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1124\/dmd.118.083329","article-title":"Equilibrative nucleoside transporter 1 (ENT1, SLC29A1) facilitates transfer of the antiretroviral drug abacavir across the placenta","volume":"46","author":"Cerveny","year":"2018","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb0525","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1021\/acs.molpharmaceut.8b00238","article-title":"Expression of concentrative nucleoside transporters (SLC28A) in the human placenta: effects of gestation age and prototype differentiation-affecting agents","volume":"15","author":"Jiraskova","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bbadis.2021.166206_bb0530","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1476-5381.2009.00336.x","article-title":"Drug transporters in the human blood-placental barrier","volume":"158","author":"Vahakangas","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0535","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425255.2015.1005073","article-title":"Regulation of drug transporter expression and function in the placenta","volume":"11","author":"Staud","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0540","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/jcph.1515","article-title":"Physiologically based pharmacokinetic models to predict maternal pharmacokinetics and fetal exposure to emtricitabine and acyclovir","volume":"60","author":"Liu","year":"2020","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0545","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1124\/dmd.117.075192","article-title":"Development of a novel maternal-fetal physiologically based pharmacokinetic model I: insights into factors that determine fetal drug exposure through simulations and sensitivity analyses","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb0550","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1124\/dmd.116.073957","article-title":"Development of a novel maternal-fetal physiologically based pharmacokinetic model II: verification of the model for passive placental permeability drugs","volume":"45","author":"Zhang","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb0555","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.reprotox.2006.01.007","article-title":"P-glycoprotein in the placenta: expression, localization, regulation and function","volume":"22","author":"Ceckova-Novotna","year":"2006","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0560","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/03602532.2010.512293","article-title":"Fetoprotective activity of breast cancer resistance protein (BCRP, ABCG2): expression and function throughout pregnancy","volume":"43","author":"Hahnova-Cygalova","year":"2011","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.bbadis.2021.166206_bb0565","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(02)00169-2","article-title":"Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview","volume":"55","author":"Schinkel","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbadis.2021.166206_bb0570","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/QAD.0000000000000112","article-title":"Interactions of tenofovir and tenofovir disoproxil fumarate with drug efflux transporters ABCB1, ABCG2, and ABCC2; role in transport across the placenta","volume":"28","author":"Neumanova","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0575","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/bdd.1993","article-title":"Role of ABCB1, ABCG2, ABCC2 and ABCC5 transporters in placental passage of zidovudine","volume":"37","author":"Neumanova","year":"2016","journal-title":"Biopharm. Drug Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb0580","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.reprotox.2015.07.070","article-title":"Effect of drug efflux transporters on placental transport of antiretroviral agent abacavir","volume":"57","author":"Neumanova","year":"2015","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0585","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1128\/AAC.00648-16","article-title":"Role of ABC and solute carrier transporters in the placental transport of lamivudine","volume":"60","author":"Ceckova","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0590","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tips.2009.10.001","article-title":"The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters","volume":"31","author":"Kis","year":"2010","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bbadis.2021.166206_bb0595","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1248\/bpb.32.1588","article-title":"P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines","volume":"32","author":"Fujimoto","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.bbadis.2021.166206_bb0600","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2013.08.054","article-title":"Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents","volume":"439","author":"Hashiguchi","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2021.166206_bb0605","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/BF01871414","article-title":"Adenosine transport and nitrobenzylthioinosine binding in human placental membrane vesicles from brush-border and basal sides of the trophoblast","volume":"119","author":"Barros","year":"1991","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0610","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF00374155","article-title":"Immunolocalisation of nucleoside transporters in human placental trophoblast and endothelial cells: evidence for multiple transporter isoforms","volume":"429","author":"Barros","year":"1995","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.bbadis.2021.166206_bb0615","doi-asserted-by":"crossref","first-page":"R1809","DOI":"10.1152\/ajpregu.00293.2007","article-title":"In situ hybridization and immunolocalization of concentrative and equilibrative nucleoside transporters in the human intestine, liver, kidneys, and placenta","volume":"293","author":"Govindarajan","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0620","doi-asserted-by":"crossref","first-page":"426","DOI":"10.2174\/157016109789043892","article-title":"Nucleoside transporter proteins","volume":"7","author":"Molina-Arcas","year":"2009","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0625","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.placenta.2017.10.011","article-title":"Role of nucleoside transporters in transplacental pharmacokinetics of nucleoside reverse transcriptase inhibitors zidovudine and emtricitabine","volume":"60","author":"Karbanova","year":"2017","journal-title":"Placenta"},{"key":"10.1016\/j.bbadis.2021.166206_bb0630","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00199-19","article-title":"Multiple drug transporters contribute to the placental transfer of emtricitabine","volume":"63","author":"Zeng","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0635","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2006.10.062","article-title":"Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters","volume":"557","author":"Yamamoto","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0640","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1124\/mol.111.071837","article-title":"Expression and distribution of nucleoside transporter proteins in the human syncytiotrophoblast","volume":"80","author":"Errasti-Murugarren","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0645","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.taap.2019.02.002","article-title":"The inhibitory effect of antiretroviral drugs on the L-carnitine uptake in human placenta","volume":"368","author":"Karahoda","year":"2019","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0650","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/toxsci\/kfs160","article-title":"Synchronized activity of organic cation transporter 3 (Oct3\/Slc22a3) and multidrug and toxin extrusion 1 (Mate1\/Slc47a1) transporter in transplacental passage of MPP+ in rat","volume":"128","author":"Ahmadimoghaddam","year":"2012","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.bbadis.2021.166206_bb0655","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.reprotox.2013.03.001","article-title":"Transfer of metformin across the rat placenta is mediated by organic cation transporter 3 (OCT3\/SLC22A3) and multidrug and toxin extrusion 1 (MATE1\/SLC47A1) protein","volume":"39","author":"Ahmadimoghaddam","year":"2013","journal-title":"Reprod. Toxicol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0660","doi-asserted-by":"crossref","first-page":"E390","DOI":"10.1152\/ajpendo.00257.2002","article-title":"Characterization and identification of steroid sulfate transporters of human placenta","volume":"284","author":"Ugele","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bbadis.2021.166206_bb0665","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.biocel.2013.06.022","article-title":"Multidrug and toxin extrusion proteins (MATE\/SLC47); role in pharmacokinetics","volume":"45","author":"Staud","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0670","doi-asserted-by":"crossref","unstructured":"D. Kojovic, V.W. N, M. Piquette-Miller, Role of elevated SFLT-1 on the regulation of placental transporters in women with pre-eclampsia, Clin Transl Sci, 13 (2020) 580-588.","DOI":"10.1111\/cts.12742"},{"key":"10.1016\/j.bbadis.2021.166206_bb0675","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00309-18","article-title":"Pharmacokinetic changes during pregnancy according to genetic variants: a prospective study in HIV-infected patients receiving atazanavir-ritonavir","volume":"62","author":"Foca","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0680","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2125.2007.03067.x","article-title":"Inhibition of placental P-glycoprotein: impact on indinavir transfer to the foetus","volume":"65","author":"Sudhakaran","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0685","doi-asserted-by":"crossref","first-page":"726593","DOI":"10.1155\/2009\/726593","article-title":"Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir\/ritonavir in the ex vivo human perfusion model","volume":"2009","author":"Ceccaldi","year":"2009","journal-title":"Obstet. Gynecol. Int."},{"key":"10.1016\/j.bbadis.2021.166206_bb0690","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.clpt.2005.04.014","article-title":"Functional role of P-glycoprotein in the human blood-placental barrier","volume":"78","author":"Molsa","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb0695","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/17425255.2018.1499726","article-title":"An update on expression and function of P-gp\/ABCB1 and BCRP\/ABCG2 in the placenta and fetus","volume":"14","author":"Han","year":"2018","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0700","doi-asserted-by":"crossref","first-page":"E57","DOI":"10.1152\/ajpendo.00696.2006","article-title":"Regulation of human organic anion transporter 4 by progesterone and protein kinase C in human placental BeWo cells","volume":"293","author":"Zhou","year":"2007","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.bbadis.2021.166206_bb0705","doi-asserted-by":"crossref","unstructured":"M. Grube, H. Meyer Zu Schwabedissen, K. Draber, D. Prager, K.U. Moritz, K. Linnemann, C. Fusch, G. Jedlitschky, H.K. Kroemer, Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta, Drug Metab Dispos, 33 (2005) 31-37.","DOI":"10.1124\/dmd.104.001560"},{"key":"10.1016\/j.bbadis.2021.166206_bb0710","unstructured":"European AIDS Clinical Society, Guidelines Version 10.0, November 2019. https:\/\/www.eacsociety.org\/files\/2019_guidelines-10.0_final.pdf. [accessed 8th January 2021]."},{"key":"10.1016\/j.bbadis.2021.166206_bb0715","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1128\/AAC.03469-14","article-title":"Population pharmacokinetics of abacavir in pregnant women","volume":"58","author":"Fauchet","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0720","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1128\/AAC.00860-08","article-title":"Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates","volume":"53","author":"Hirt","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0725","doi-asserted-by":"crossref","unstructured":"A.P. Colbers, D.A. Hawkins, A. Gingelmaier, K. Kabeya, J.K. Rockstroh, C. Wyen, K. Weizsacker, S.T. Sadiq, J. Ivanovic, C. Giaquinto, G.P. Taylor, J. Molto, D.M. Burger, P. network, The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women, AIDS, 27 (2013) 739-748.","DOI":"10.1097\/QAD.0b013e32835c208b"},{"key":"10.1016\/j.bbadis.2021.166206_bb0730","doi-asserted-by":"crossref","first-page":"j3961","DOI":"10.1136\/bmj.j3961","article-title":"Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline","volume":"358","author":"Siemieniuk","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.bbadis.2021.166206_bb0735","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/jac\/dku400","article-title":"Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women","volume":"70","author":"Colbers","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0740","unstructured":"World Health Organization, WHO recommends dolutegravir as preferred HIV treatment option in all populations, https:\/\/www.who.int\/news\/item\/22-07-2019-who-recommends-dolutegravir-as-preferred-hiv-treatment-option-in-all-populations, accessed 7th January 2021."},{"key":"10.1016\/j.bbadis.2021.166206_bb0745","doi-asserted-by":"crossref","unstructured":"E.C. Joao, R.L. Morrison, D.E. Shapiro, N. Chakhtoura, M.I.S. Gouvea, B.T.M. de Lourdes, T.L. Fuller, B.T. Mmbaga, J.S. Ngocho, B.N. Njau, A. Violari, R. Mathiba, Z. Essack, J.H.S. Pilotto, L.F. Moreira, M.J. Rolon, P. Cahn, S. Prommas, T.R. Cressey, K. Chokephaibulkit, P. Werarak, L. Laimon, R. Hennessy, L.M. Frenkel, P. Anthony, B.M. Best, G.K. Siberry, M. Mirochnick, Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial, Lancet HIV, 7 (2020) e322-e331.","DOI":"10.1016\/S2352-3018(20)30038-2"},{"key":"10.1016\/j.bbadis.2021.166206_bb0750","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40121-017-0184-8","article-title":"Pharmacokinetics, antiviral activity, and safety of rilpivirine in pregnant women with HIV-1 infection: results of a phase 3b, multicenter, open-label study","volume":"7","author":"Osiyemi","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb0755","doi-asserted-by":"crossref","unstructured":"S. Schalkwijk, A. Colbers, D. Konopnicki, A. Gingelmaier, J. Lambert, M. van der Ende, J. Molto, D. Burger, H.I.V.i.p.w.N. Pharmacokinetics of newly developed antiretroviral agents in, Lowered rilpivirine exposure during the third trimester of pregnancy in human immunodeficiency virus type 1-infected women, Clin Infect Dis, 65 (2017) 1335-1341.","DOI":"10.1093\/cid\/cix534"},{"key":"10.1016\/j.bbadis.2021.166206_bb0760","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJMoa1905230","article-title":"Neural-tube defects and antiretroviral treatment regimens in Botswana","volume":"381","author":"Zash","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0765","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1056\/NEJMc1807653","article-title":"Neural-tube defects with Dolutegravir treatment from the time of conception","volume":"379","author":"Zash","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0770","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/QAD.0000000000002767","article-title":"Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV: results from IMPAACT P1026s","volume":"35","author":"Brooks","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0775","doi-asserted-by":"crossref","unstructured":"A. Colbers, B. Best, S. Schalkwijk, J. Wang, A. Stek, C. Hidalgo Tenorio, D. Hawkins, G. Taylor, R. Kreitchmann, S. Burchett, A. Haberl, K. Kabeya, M. van Kasteren, E. Smith, E. Capparelli, D. Burger, M. Mirochnick, P. Network, I.S.T. the, Maraviroc Pharmacokinetics in HIV-1-Infected Pregnant Women, Clin Infect Dis, 61 (2015) 1582-1589.","DOI":"10.1093\/cid\/civ587"},{"key":"10.1016\/j.bbadis.2021.166206_bb0780","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejogrb.2015.11.015","article-title":"Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the antiretroviral pregnancy registry","volume":"197","author":"Vannappagari","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0785","doi-asserted-by":"crossref","unstructured":"P.L. Williams, M.J. Crain, C. Yildirim, R. Hazra, R.B. Van Dyke, K. Rich, J.S. Read, E. Stuard, M. Rathore, H.A. Mendez, D.H. Watts, H.I.V.A.C.S. Pediatric, Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants, JAMA Pediatr, 169 (2015) 48-55.","DOI":"10.1001\/jamapediatrics.2014.1889"},{"key":"10.1016\/j.bbadis.2021.166206_bb0790","doi-asserted-by":"crossref","unstructured":"J. Sibiude, J. Le Chenadec, D. Bonnet, R. Tubiana, A. Faye, C. Dollfus, L. Mandelbrot, S. Delmas, N. Lelong, B. Khoshnood, J. Warszawski, S. Blanche, A. French National Agency for Research on, T. Viral Hepatitis French Perinatal Cohort\/Protease Inhibitor Monotherapy Evaluation, In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial, Clin Infect Dis, 61 (2015) 270-280.","DOI":"10.1093\/cid\/civ260"},{"issue":"Suppl. 2","key":"10.1016\/j.bbadis.2021.166206_bb0795","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1097\/QAD.0000000000000231","article-title":"Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis","volume":"28","author":"Ford","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0800","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11481-019-09880-z","article-title":"Evaluating neurodevelopmental consequences of perinatal exposure to antiretroviral drugs: current challenges and new approaches","volume":"16","author":"Schnoll","year":"2021","journal-title":"J. NeuroImmune Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0805","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s11904-019-00459-0","article-title":"Growth and neurodevelopment of HIV-exposed uninfected children: a conceptual framework","volume":"16","author":"Wedderburn","year":"2019","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"10.1016\/j.bbadis.2021.166206_bb0810","doi-asserted-by":"crossref","unstructured":"P.L. Williams, C. Yildirim, E.G. Chadwick, R.B. Van Dyke, R. Smith, K.F. Correia, A. DiPerna, G.R. Seage, 3rd, R. Hazra, C.S. Crowell, A.R.T.T.s.o.t.P.H.I.V.A.C.S. Surveillance Monitoring for, Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study, Lancet HIV, 7 (2020) e49-e58.","DOI":"10.1016\/S2352-3018(19)30340-6"},{"key":"10.1016\/j.bbadis.2021.166206_bb0815","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1097\/INF.0000000000000251","article-title":"First trimester exposure to antiretroviral therapy and risk of birth defects","volume":"33","author":"Phiri","year":"2014","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.bbadis.2021.166206_bb0820","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41398-019-0420-y","article-title":"Neurodevelopmental and behavioral consequences of perinatal exposure to the HIV drug efavirenz in a rodent model","volume":"9","author":"van de Wijer","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.bbadis.2021.166206_bb0825","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/INF.0000000000002332","article-title":"In utero efavirenz exposure and neurodevelopmental outcomes in HIV-exposed uninfected children in Botswana","volume":"38","author":"Cassidy","year":"2019","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.bbadis.2021.166206_bb0830","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/j.1468-1293.2011.00945.x","article-title":"Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress","volume":"13","author":"Ross","year":"2012","journal-title":"HIV Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0835","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/00002030-200308150-00006","article-title":"G. French perinatal cohort study, persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort","volume":"17","author":"Barret","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb0840","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/S0140-6736(99)07219-0","article-title":"Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues","volume":"354","author":"Blanche","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166206_bb0845","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s40262-015-0257-3","article-title":"Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations","volume":"54","author":"Decloedt","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb0850","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/1096-9926(200101)63:1<26::AID-TERA1005>3.0.CO;2-G","article-title":"Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT)\u00a0+\u00a0lamivudine (3TC) treatment in mice","volume":"63","author":"Venerosi","year":"2001","journal-title":"Teratology"},{"key":"10.1016\/j.bbadis.2021.166206_bb0855","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1093\/cid\/ciz605","article-title":"Children exposed or unexposed to human immunodeficiency virus: weight, height, and body mass index during the first 5 years of life-a Danish nationwide cohort","volume":"70","author":"Moseholm","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bbadis.2021.166206_bb0860","doi-asserted-by":"crossref","unstructured":"J. Jao, D.L. Jacobson, W. Yu, W. Borkowsky, M.E. Geffner, E.J. McFarland, K. Patel, P.L. Williams, T. Miller, H.I.V.A.C.S. Pediatric, A comparison of metabolic outcomes between obese HIV-exposed uninfected youth from the PHACS SMARTT study and HIV-unexposed youth from the NHANES study in the United States, J Acquir Immune Defic Syndr, 81 (2019) 319\u2013327.","DOI":"10.1097\/QAI.0000000000002018"},{"key":"10.1016\/j.bbadis.2021.166206_bb0865","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/aid.2015.0281","article-title":"Long-term effects of in utero antiretroviral exposure: systolic and diastolic function in HIV-exposed uninfected youth","volume":"32","author":"Guerra","year":"2016","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"10.1016\/j.bbadis.2021.166206_bb0870","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00126334-200204010-00001","article-title":"Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys","volume":"29","author":"Olivero","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0875","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/em.20266","article-title":"Elevated frequencies of micronucleated erythrocytes in infants exposed to zidovudine in utero and postpartum to prevent mother-to-child transmission of HIV","volume":"48","author":"Witt","year":"2007","journal-title":"Environ. Mol. Mutagen."},{"key":"10.1016\/j.bbadis.2021.166206_bb0880","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/QAI.0000000000000695","article-title":"Cancer among children with perinatal exposure to HIV and antiretroviral medications-New Jersey, 1995\u20132010","volume":"70","author":"Ivy","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0885","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biocel.2018.09.016","article-title":"Trophoblast: the central unit of fetal growth, protection and programming","volume":"105","author":"Staud","year":"2018","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0890","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0231938","article-title":"Placental growth disorders and perinatal adverse outcomes in Brazilian HIV-infected pregnant women","volume":"15","author":"Dos Reis","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2021.166206_bb0895","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/tmi.12858","article-title":"Placental pathology in HIV infection at term: a comparison with HIV-uninfected women","volume":"22","author":"Kalk","year":"2017","journal-title":"Tropical Med. Int. Health"},{"key":"10.1016\/j.bbadis.2021.166206_bb0900","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/QAI.0000000000001871","article-title":"Placental structure in preterm birth among HIV-positive versus HIV-negative women in Kenya","volume":"80","author":"Obimbo","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0905","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/jphp.12495","article-title":"Long-term administration of tenofovir or emtricitabine to pregnant rats; effect on Abcb1a, Abcb1b and Abcg2 expression in the placenta and in maternal and fetal organs","volume":"68","author":"Cerveny","year":"2016","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb0910","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1093\/jac\/dku483","article-title":"Tenofovir during pregnancy in rats: a novel pathway for programmed hypertension in the offspring","volume":"70","author":"Gois","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0915","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/humrep\/deaa151","article-title":"Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies","volume":"35","author":"Kala","year":"2020","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.bbadis.2021.166206_bb0920","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2016.04.028","article-title":"Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz","volume":"110","author":"Dalwadi","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbadis.2021.166206_bb0925","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13478","article-title":"Serotonin homeostasis in the materno-foetal interface at term: role of transporters (SERT\/SLC6A4 and OCT3\/SLC22A3) and monoamine oxidase A (MAO-A) in uptake and degradation of serotonin by human and rat term placenta","volume":"229","author":"Karahoda","year":"2020","journal-title":"Acta Physiol (Oxford)"},{"key":"10.1016\/j.bbadis.2021.166206_bb0930","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s002130000585","article-title":"Prenatal AZT or 3TC and mouse development of locomotor activity and hot-plate responding upon administration of the GABA(A) receptor agonist muscimol","volume":"153","author":"Ricceri","year":"2001","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbadis.2021.166206_bb0935","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1177\/0897190017710519","article-title":"A review of the efficacy and safety of Genvoya(R) (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) in the management of HIV-1 infection","volume":"31","author":"Angione","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"10.1016\/j.bbadis.2021.166206_bb0940","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results","volume":"75","author":"Arribas","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0945","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1128\/AAC.00370-11","article-title":"Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women","volume":"56","author":"Benaboud","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb0950","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002895","article-title":"Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: a randomised trial (DolPHIN-1 study)","volume":"16","author":"Waitt","year":"2019","journal-title":"PLoS Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb0955","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166206_bb0960","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2021.166206_bb0965","doi-asserted-by":"crossref","unstructured":"T. Farrow, C. Deaton, N. Nguyen, M. Serejo, D. Muramoto, A. van Troostenburg, L. Ng, L. Liu, H. Martin, M. Das, Cumulative safety review of elvitegravir and bictegravir use during pregnancy and risk of neural tube defects P030. HIV Glasgow 2018, 28-31 October 2018, Glasgow, UK., J Int AIDS Soc, 21 Suppl 8 (2018) e25187.","DOI":"10.1002\/jia2.25187"},{"key":"10.1016\/j.bbadis.2021.166206_bb0970","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1093\/cid\/ciq243","article-title":"The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection","volume":"52","author":"Gardner","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 2","key":"10.1016\/j.bbadis.2021.166206_bb0975","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1097\/QAI.0000000000001234","article-title":"Longitudinal HIV care trajectories in North Carolina","volume":"74","author":"Powers","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0980","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40265-020-01284-1","article-title":"Advances in long-acting agents for the treatment of HIV infection","volume":"80","author":"Rana","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2021.166206_bb0985","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/apc.2018.0198","article-title":"Long-acting injectable antiretroviral treatment acceptability and preferences: a qualitative study among US providers, adults living with HIV, and parents of youth living with HIV","volume":"33","author":"Simoni","year":"2019","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.bbadis.2021.166206_bb0990","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/QAI.0000000000001896","article-title":"Interest of youth living with HIV in long-acting antiretrovirals","volume":"80","author":"Weld","year":"2019","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb0995","doi-asserted-by":"crossref","unstructured":"D.A. Margolis, J. Gonzalez-Garcia, H.J. Stellbrink, J.J. Eron, Y. Yazdanpanah, D. Podzamczer, T. Lutz, J.B. Angel, G.J. Richmond, B. Clotet, F. Gutierrez, L. Sloan, M.S. Clair, M. Murray, S.L. Ford, J. Mrus, P. Patel, H. Crauwels, S.K. Griffith, K.C. Sutton, D. Dorey, K.Y. Smith, P.E. Williams, W.R. Spreen, Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial, Lancet, 390 (2017) 1499\u20131510.","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"10.1016\/j.bbadis.2021.166206_bb1000","doi-asserted-by":"crossref","unstructured":"G. van 't Klooster, E. Hoeben, H. Borghys, A. Looszova, M.P. Bouche, F. van Velsen, L. Baert, Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation, Antimicrob Agents Chemother, 54 (2010) 2042-2050.","DOI":"10.1128\/AAC.01529-09"},{"key":"10.1016\/j.bbadis.2021.166206_bb1005","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1056\/NEJMp1808729","article-title":"Ibalizumab in multidrug-resistant HIV - accepting uncertainty","volume":"379","author":"Sheikh","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb1010","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMoa1711460","article-title":"Phase 3 study of ibalizumab for multidrug-resistant HIV-1","volume":"379","author":"Emu","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb1015","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25372","article-title":"Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?","volume":"22","author":"Fairlie","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.bbadis.2021.166206_bb1020","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1124\/dmd.115.064824","article-title":"Potent and selective inhibition of plasma membrane monoamine transporter by HIV protease inhibitors","volume":"43","author":"Duan","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb1025","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1128\/AAC.48.11.4332-4336.2004","article-title":"Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women","volume":"48","author":"Chappuy","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1030","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1124\/jpet.108.146225","article-title":"Transport of lamivudine [(-)-beta-L-2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3","volume":"329","author":"Minuesa","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb1035","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/jac\/dkt095","article-title":"Transplacental passage of etravirine and maraviroc in a multidrug-experienced HIV-infected woman failing on darunavir-based HAART in late pregnancy","volume":"68","author":"Calcagno","year":"2013","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1040","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/00498254.2016.1158886","article-title":"Emtricitabine is a substrate of MATE1 but not of OCT1, OCT2, P-gp, BCRP or MRP2 transporters","volume":"47","author":"Reznicek","year":"2017","journal-title":"Xenobiotica"},{"key":"10.1016\/j.bbadis.2021.166206_bb1045","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02213-16","article-title":"Pharmacokinetics and placental transfer of llvitegravir, dolutegravir, and other antiretrovirals during pregnancy","volume":"61","author":"Rimawi","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1067\/mob.2001.108344","article-title":"Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunodeficiency virus-infected pregnant women","volume":"184","author":"Mandelbrot","year":"2001","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.bbadis.2021.166206_bb1055","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1128\/AAC.01523-08","article-title":"Genital tract, cord blood, and amniotic fluid exposures of seven antiretroviral drugs during and after pregnancy in human immunodeficiency virus type 1-infected women","volume":"53","author":"Yeh","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1060","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s40262-014-0185-7","article-title":"Protecting the fetus against HIV infection: a systematic review of placental transfer of antiretrovirals","volume":"53","author":"McCormack","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb1065","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1124\/jpet.300.3.918","article-title":"Human organic anion transporters and human organic cation transporters mediate renal antiviral transport","volume":"300","author":"Takeda","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb1070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1177\/135965350400900617","article-title":"Interaction of nucleoside inhibitors of HIV-1 reverse transcriptase with the concentrative nucleoside transporter-1 (SLC28A1)","volume":"9","author":"Cano-Soldado","year":"2005","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.bbadis.2021.166206_bb1075","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bcp.2007.01.027","article-title":"Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein","volume":"73","author":"Storch","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbadis.2021.166206_bb1080","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1093\/jac\/dkl474","article-title":"Modulation of human BCRP (ABCG2) activity by anti-HIV drugs","volume":"59","author":"Weiss","year":"2007","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1085","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/QAI.0b013e31823ff052","article-title":"Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum","volume":"59","author":"Cressey","year":"2012","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb1090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0202706","article-title":"Efavirenz reduces renal excretion of lamivudine in rats by inhibiting organic cation transporters (OCT, Oct) and multidrug and toxin extrusion proteins (MATE, Mate)","volume":"13","author":"Ceckova","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2021.166206_bb1095","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/QAD.0000000000000100","article-title":"Pharmacokinetics, safety and transplacental passage of rilpivirine in pregnancy: two cases","volume":"28","author":"Colbers","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb1100","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00837-17","article-title":"MDR1 and BCRP transporter-mediated drug-drug interaction between rilpivirine and abacavir and effect on intestinal absorption","volume":"61","author":"Reznicek","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1105","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/jac\/dkq209","article-title":"Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines","volume":"65","author":"Bierman","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1110","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1468-1293.2011.00927.x","article-title":"Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women","volume":"12","author":"Conradie","year":"2011","journal-title":"HIV Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb1115","doi-asserted-by":"crossref","unstructured":"J. Ivanovic, E. Nicastri, M.M. Anceschi, P. Ascenzi, F. Signore, G. Pisani, C. Vallone, E. Mattia, S. Notari, M. Tempestilli, L.P. Pucillo, P. Narciso, Pregnancy, H.I.V.I. Newborn Clinical Outcome Group in, Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women, Curr HIV Res, 7 (2009) 620\u2013625.","DOI":"10.2174\/157016209789973628"},{"key":"10.1016\/j.bbadis.2021.166206_bb1120","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejogrb.2011.02.005","article-title":"Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia","volume":"157","author":"Mandelbrot","year":"2011","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.bbadis.2021.166206_bb1125","doi-asserted-by":"crossref","first-page":"5617","DOI":"10.1128\/AAC.03184-14","article-title":"Placental transfer of darunavir in an ex vivo human cotyledon perfusion model","volume":"58","author":"Mandelbrot","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1130","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/hiv.12047","article-title":"Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir\/ritonavir 600\/100\u00a0mg administered twice daily","volume":"15","author":"Zorrilla","year":"2014","journal-title":"HIV Med."},{"key":"10.1016\/j.bbadis.2021.166206_bb1135","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/QAD.0000000000001755","article-title":"Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV","volume":"32","author":"Mulligan","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.bbadis.2021.166206_bb1140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb1145","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/jac\/dkw215","article-title":"P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load","volume":"71","author":"Minuesa","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1150","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1128\/AAC.04594-14","article-title":"Raltegravir permeability across blood-tissue barriers and the potential role of drug efflux transporters","volume":"59","author":"Hoque","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1155","doi-asserted-by":"crossref","unstructured":"M.I. Blonk, A.P. Colbers, C. Hidalgo-Tenorio, K. Kabeya, K. Weizsacker, A.E. Haberl, J. Molto, D.A. Hawkins, M.E. van der Ende, A. Gingelmaier, G.P. Taylor, J. Ivanovic, C. Giaquinto, D.M. Burger, H.I.V.I.P.W.P.N. Pharmacokinetics of Newly Developed Antiretroviral Agents in, P. Network, Raltegravir in HIV-1-Infected Pregnant Women: Pharmacokinetics, Safety, and Efficacy, Clin Infect Dis, 61 (2015) 809\u2013816.","DOI":"10.1093\/cid\/civ366"},{"key":"10.1016\/j.bbadis.2021.166206_bb1160","doi-asserted-by":"crossref","unstructured":"D.H. Watts, A. Stek, B.M. Best, J. Wang, E.V. Capparelli, T.R. Cressey, F. Aweeka, P. Lizak, R. Kreitchmann, S.K. Burchett, D.E. Shapiro, E. Hawkins, E. Smith, M. Mirochnick, I.s.s. team, Raltegravir pharmacokinetics during pregnancy, J Acquir Immune Defic Syndr, 67 (2014) 375-381.","DOI":"10.1097\/QAI.0000000000000318"},{"key":"10.1016\/j.bbadis.2021.166206_bb1165","doi-asserted-by":"crossref","unstructured":"D.F. Clarke, E.P. Acosta, M.L. Rizk, Y.J. Bryson, S.A. Spector, L.M. Mofenson, E. Handelsman, H. Teppler, C. Welebob, D. Persaud, M.P. Cababasay, J. Wang, M. Mirochnick, A.C.T.P.S.T. International Maternal Pediatric Adolescent, Raltegravir pharmacokinetics in neonates following maternal dosing, J Acquir Immune Defic Syndr, 67 (2014) 310-315.","DOI":"10.1097\/QAI.0000000000000316"},{"key":"10.1016\/j.bbadis.2021.166206_bb1170","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1128\/AAC.02049-13","article-title":"Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation","volume":"58","author":"Rizk","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1175","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/QAI.0000000000001699","article-title":"Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals","volume":"78","author":"Begley","year":"2018","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb1180","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.placenta.2016.09.019","article-title":"Etravirine inhibits ABCG2 drug transporter and affects transplacental passage of tenofovir disoproxil fumarate","volume":"47","author":"Reznicek","year":"2016","journal-title":"Placenta"},{"key":"10.1016\/j.bbadis.2021.166206_bb1185","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1128\/AAC.01527-10","article-title":"Interaction potential of etravirine with drug transporters assessed in vitro","volume":"55","author":"Zembruski","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bbadis.2021.166206_bb1190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/11534740-000000000-00000","article-title":"Pharmacokinetic interactions between etravirine and non-antiretroviral drugs","volume":"50","author":"Kakuda","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb1195","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/10895940-000000000-00000","article-title":"Clinical pharmacokinetics and pharmacodynamics of etravirine","volume":"48","author":"Scholler-Gyure","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2021.166206_bb1200","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QAI.0000000000001068","article-title":"Pharmacokinetics of total and unbound etravirine in HIV-1-infected pregnant women","volume":"73","author":"Ramgopal","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.bbadis.2021.166206_bb1205","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/dmd.119.087684","article-title":"Interactions between maraviroc and the ABCB1, ABCG2, and ABCC2 transporters: an important role in transplacental pharmacokinetics","volume":"47","author":"Tupova","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bbadis.2021.166206_bb1210","doi-asserted-by":"crossref","first-page":"7666","DOI":"10.1128\/AAC.01634-15","article-title":"Effects of antiviral drugs on organic anion transport in human placental BeWo cells","volume":"59","author":"Nabekura","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443921001393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443921001393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:36:28Z","timestamp":1777584988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443921001393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":242,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0925443921001393"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2021.166206","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV in pregnancy: Mother-to-child transmission, pharmacotherapy, and toxicity","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2021.166206","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"166206"}}